 Home > Biochemistry News > Biotechnology News > Eleva advances clinical development of difficult-to-express high-potential proteins

Eleva advances clinical development of difficult-to-express high-potential proteins

 Last Update: 2021-10-21
 Source: Internet
 Author: User

Tags

zoster recombinant vaccine

ladder plant protein

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Freiburg, Germany, October 12, 2021/PRNewswire/ - The outstanding biologics manufacturer Eleva is advancing its drug candidates (such as immunomodulatory factor H) into the clinical phase and is cooperating with many pharmaceutical partners
.

Eleva's moss-based platform is ideal for producing drug candidates that are difficult to express but have therapeutic prospects

Eleva recently expanded its production capacity in order to implement clinical studies of drug candidates
.

The earliest of these is Factor H, which will be developed in Phase II

Eleva's moss-based platform provides unique advantages for recombinant protein development.

Such as:

The bryoose structure inherently lacks core α-1,6 fucose (a known allergen), and any other glycan can be "humanized"
.

This will result in good organ uptake

Eleva is using these advantages to produce complex proteins for future treatments (such as second-generation tumor therapy drugs), or virus-like particles (VLP) for vaccine development
.

Ralf Smit, Chief Brand Officer of Eleva, said: "With the continuous expansion of production scale, we are currently able to cooperate with many partners in the pharmaceutical industry to develop therapeutic proteins that are difficult to express
.

We look forward to our moss platform being able to release complex drug candidates.

About Eleva

Headquartered in Freiburg, Germany, Eleva is committed to co-developing new biological therapies with pharmaceutical partners
.

This private company uses its unique moss-based production platform to produce top biological agents such as antibodies, replacement enzymes or fusion toxins

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.